Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18
omecamtiv mecarbil
Biotech
Investors say 'no bueno' to Cytokinetics' complex Royalty deal
Cytokinetics has now all but assured that a buyout is not happening with a $575 million Royalty Pharma funding deal that drew the ire of investors.
Annalee Armstrong
May 23, 2024 10:36am
Cytokinetics' pipeline tumble persists after ALS med flops
Mar 31, 2023 11:03am
FDA advisers nix Cytokinetics heart failure med, subgroup data
Dec 13, 2022 8:04pm
FDA day nears for Cytokinetics' heart failure drug
Dec 9, 2022 2:12pm
Cytokinetics' heart failure drug delayed as FDA seeks more time
Jun 17, 2022 11:00am
Cytokinetics, Royalty partner on heart failure drug for $450M
Jan 7, 2022 9:55am
